AI assistant
Imunon, Inc. — Director's Dealing 2025
Sep 9, 2025
35124_dirs_2025-09-09_36f3d385-ab26-42e3-b6ed-0ed2f8251228.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Imunon, Inc. (IMNN)
CIK: 0000749647
Period of Report: 2025-09-06
Reporting Person: Lindborg Stacy (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-09-06 | Common Stock | M | 1667 | — | Acquired | 3584 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-09-06 | Restricted Stock | $ | M | 1667 | Disposed | Common Stock (1667) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 234 | Indirect |
Footnotes
F1: Acquisition of common stock resulting from vesting of 100% of the restricted stock granted to Ms. Lindborg on September 6, 2024.
F2: Each restricted stock share represents a contingent right to receive one share of Imunon, Inc.'s common stock.
F3: On September 6, 2024, Ms. Lindborg received restricted stock representing 1,667 shares (as adjusted for the reverse stock split) subject to a one-year vesting schedule, vesting 100% on the first anniversary of the grant date. As restricted stock shares vest, the vested shares are automatically converted to vested common stock on a one-for-one basis on the vesting date.